Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimize@Home
NCT06094920Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin, finerenone in type 2 diabetes mellitus (T2DM), albuminuria, chronic kidney disease (CKD), sponsored by University Medical Center Groningen. Started Jul 2024; status: completed.
02
Drugs
empagliflozinfinerenone
03
Conditions
type 2 diabetes mellitus (T2DM)albuminuriachronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06094920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094920.